Friday, 15 Nov 2019

You are here

Adherence to Gout Therapies Painfully Low

There are numerous, highly effective urate-lowering therapies (ULT) to treat and prevent gout attacks, yet gout remains the most common undertreated and poorly treated form of arthritis.  While some of this responsibility lies with healthcare providers, patient factors may color the outcomes.

A retrospective study of the large UK Clinical Practice Research Datalink (1987–2014) sought to assess patient medication compliance in gout and found that adherence to allopurinol in gout is poor, especially among females and younger patients and those with fewer comorbidities. 

They examined newly diagnosed gout patients, ⩾40 years and starting allopurinol (n = 48 280). Non-persistence was measured as amedication gap of ⩾90 days after 1 and 5 years. Non-adherence identified patients whose complied with treatment <80% over the observation period. 

From year 1 to year 5, non-persistence increased from 38.5% to 56.9% after allopurinol initiation. After a first gap in therapy, 43.3% restarted allopurinol therapy within 1 year. Yet again only 52.3% persisted for 1 year.

Non-persistence and non-adherence were higher in females, current smokers.  Persistence and adherence were higher in older and overweight gout patients, those on anti-hypertensives or colchicine and those with comorbidities (dementia, diabetes or dyslipidemia). 

Another metanalysis of 24 studies similarly showed that ULT adherence was less than 48% and  that non-persistence ranged from 54% to 87%. In some of these studies, adherence positively correlated with older age, more comorbidities, and the presence of diabetes or hypertension. (Citation source: http://bit.ly/2wtjN1f)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.